2026 Global: Liquid Biopsy Market-Competitive Review (2032) report
Description
The 2026 Global: Liquid Biopsy Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Guardant Health, headquartered in Redwood City, United States, has become a benchmark in cfDNA profiling with its Guardant360 and liquid biopsy assays, widely used to guide targeted therapies in solid tumors. The company's blood-based approach emphasizes noninvasiveness, serial monitoring, and integration with clinical records to support treatment decisions. Grail, based in Menlo Park, United States, pursues early cancer detection through sequencing and longitudinal risk assessment, aiming to shift outcomes toward pre-symptomatic intervention. Illumina, headquartered in San Diego, United States, provides sequencing platforms and bioinformatics infrastructure that enable many liquid biopsy tests, including assay development, large-scale population screening programs, and collaborations with partners for oncology diagnostics. Freenome, located in South San Francisco, United States, blends cfDNA signals with methylation and multi-omics data to improve early detection, monitoring, and risk stratification for several cancer types. Thermo Fisher Scientific, based in Waltham, United States, offers cfDNA workflows that support laboratories developing biopsy assays.
Qiagen N.V., headquartered in Hilden, Germany, markets a broad portfolio of cfDNA extraction kits, sequencing pipelines, and companion diagnostics that underpin many liquid biopsy workflows, including panel development and clinical-grade assays. Biocept, Inc., headquartered in San Diego, United States, provides CTC- and cfDNA-based tests such as the Access molecular platform and has focused on minimally invasive cancer monitoring for metastatic disease. Caris Life Sciences, based in Phoenix, United States, integrates tissue and liquid biopsy data with comprehensive genomic profiling to guide personalized treatment decisions, particularly through its Caris Assay portfolio. Biocartis N.V., headquartered in Mechelen, Belgium, develops automated cartridge-based platforms for ctDNA testing and multi-gene panels, enabling scalable clinical workflows. Genetron Health, based in Beijing, China, delivers ctDNA and methylation-based assays for cancer screening, prognosis, and treatment decision support in the Chinese market and beyond. The company collaborates with hospitals and research institutions to expand access and validation globally today.
Together, the ten companies anchor a rapidly evolving liquid biopsy ecosystem that spans cfDNA methylation, circulating tumor cell capture, and exosome analysis. In the United States, Guardant Health, Grail, Illumina, Freenome, Thermo Fisher, Biocept, and Caris Life Sciences contribute to diagnostic development, validation, and integration into routine oncology care, supported by established regulatory processes and payer pathways. In Europe, Biocartis and Qiagen advance automated, scalable testing platforms and standardized workflows that enable multi-gene panels and companion diagnostics across centers, enhancing reproducibility. Genetron Health represents the fast-growing Asian segment, emphasizing China’s vast patient base and partnerships to drive assay development, validation, and clinical adoption. Collectively, these firms delineate a global map of investment, collaboration and innovation, with ongoing consolidation and cross-border research shaping the future of noninvasive cancer management. These development trajectories will determine patient access, economic value, and the integration of liquid biopsy into standard oncology practice worldwide in markets.
Guardant Health, headquartered in Redwood City, United States, has become a benchmark in cfDNA profiling with its Guardant360 and liquid biopsy assays, widely used to guide targeted therapies in solid tumors. The company's blood-based approach emphasizes noninvasiveness, serial monitoring, and integration with clinical records to support treatment decisions. Grail, based in Menlo Park, United States, pursues early cancer detection through sequencing and longitudinal risk assessment, aiming to shift outcomes toward pre-symptomatic intervention. Illumina, headquartered in San Diego, United States, provides sequencing platforms and bioinformatics infrastructure that enable many liquid biopsy tests, including assay development, large-scale population screening programs, and collaborations with partners for oncology diagnostics. Freenome, located in South San Francisco, United States, blends cfDNA signals with methylation and multi-omics data to improve early detection, monitoring, and risk stratification for several cancer types. Thermo Fisher Scientific, based in Waltham, United States, offers cfDNA workflows that support laboratories developing biopsy assays.
Qiagen N.V., headquartered in Hilden, Germany, markets a broad portfolio of cfDNA extraction kits, sequencing pipelines, and companion diagnostics that underpin many liquid biopsy workflows, including panel development and clinical-grade assays. Biocept, Inc., headquartered in San Diego, United States, provides CTC- and cfDNA-based tests such as the Access molecular platform and has focused on minimally invasive cancer monitoring for metastatic disease. Caris Life Sciences, based in Phoenix, United States, integrates tissue and liquid biopsy data with comprehensive genomic profiling to guide personalized treatment decisions, particularly through its Caris Assay portfolio. Biocartis N.V., headquartered in Mechelen, Belgium, develops automated cartridge-based platforms for ctDNA testing and multi-gene panels, enabling scalable clinical workflows. Genetron Health, based in Beijing, China, delivers ctDNA and methylation-based assays for cancer screening, prognosis, and treatment decision support in the Chinese market and beyond. The company collaborates with hospitals and research institutions to expand access and validation globally today.
Together, the ten companies anchor a rapidly evolving liquid biopsy ecosystem that spans cfDNA methylation, circulating tumor cell capture, and exosome analysis. In the United States, Guardant Health, Grail, Illumina, Freenome, Thermo Fisher, Biocept, and Caris Life Sciences contribute to diagnostic development, validation, and integration into routine oncology care, supported by established regulatory processes and payer pathways. In Europe, Biocartis and Qiagen advance automated, scalable testing platforms and standardized workflows that enable multi-gene panels and companion diagnostics across centers, enhancing reproducibility. Genetron Health represents the fast-growing Asian segment, emphasizing China’s vast patient base and partnerships to drive assay development, validation, and clinical adoption. Collectively, these firms delineate a global map of investment, collaboration and innovation, with ongoing consolidation and cross-border research shaping the future of noninvasive cancer management. These development trajectories will determine patient access, economic value, and the integration of liquid biopsy into standard oncology practice worldwide in markets.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
